Taro to hold meetings for approval of merger with Sun Pharmaceutical Industries If the merger is completed, Taro will become a privately held company and its shares will no longer be listed on the NYSE. Placer.ai weighs in on Q1 2024 retail sector performanceRetail’s positive Q1 performance leaves plenty of room for optimism about what’s in store for the rest of 2024, Pacer.ai's Q1 study finds. Fresenius debuts Actemra biosimilar Tyenne, for use in the treatment of chronic autoimmune diseases, is available in an intravenous formulation. Hy-Vee to acquire Strack & Van Til Food Market chain The acquisition will add 22 stores to Hy-Vee’s portfolio. ANI debuts generic Fleqsuvy Generic Fleqsuvy is a treatment for spasticity from multiple sclerosis, spinal cord injuries and other spinal cord diseases. Avenacy debuts generic DDAVP Desmopressin acetate for injection is multi-indicated for patients with central diabetes insipidus, hemophilia A and von Willebrand’s disease. Retail sales steadily climbing Data released by the U.S. Census Bureau shows retail sales rose 1.1% in March and were up 3.2% year-over-year. Costco sales rise in March Total company sales for the month were $23.48 billion, an increase of 9.4% from the comparable period the previous year. NCPA launches CORE leadership program Skills in financials, operations, marketing and leadership are the focus of the program. Samsung Bioepis releases Q2 2024 U.S. biosimilar market report As of April 2024, the FDA has approved a total of 48 biosimilars across 15 unique biological molecules, and of the 48 approvals, 38 biosimilars have launched in the U.S. market, per the report. First Previous 38 39 40 41 42 Next Last
